Jim Simons
HRTX icon

Jim Simons’s Heron Therapeutics HRTX Stock Holding History

Jim Simons’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Sell
1,718,300
-197,600
-10% -$229K ﹤0.01% 2104
2025
Q4 		$2.49M Sell
1,915,900
-939,099
-33% -$1.16M ﹤0.01% 1730
2025
Q3 		$3.6M Buy
2,854,999
+165,660
+6% +$263K ﹤0.01% 1677
2025
Q2 		$5.57M Buy
2,689,339
+414,839
+18% +$847K 0.01% 1458
2025
Q1 		$5M Buy
2,274,500
+1,085,700
+91% +$2.11M 0.01% 1427
2024
Q4 		$1.82M Sell
1,188,800
-819,398
-41% -$1.33M ﹤0.01% 2120
2024
Q3 		$4M Buy
2,008,198
+14,398
+0.7% +$34.4K 0.01% 1587
2024
Q2 		$6.98M Sell
1,993,800
-412,686
-17% -$1.27M 0.01% 1114
2024
Q1 		$6.67M Buy
2,406,486
+523,186
+28% +$1.32M 0.01% 1233
2023
Q4 		$3.2M Buy
1,883,300
+1,592,000
+547% +$1.75M 0.01% 1641
2023
Q3 		$300K Sell
291,300
-767,800
-72% -$1.09M ﹤0.01% 2933
2023
Q2 		$1.23M Sell
1,059,100
-81,736
-7% -$146K ﹤0.01% 2338
2023
Q1 		$1.72M Buy
1,140,836
+814,336
+249% +$2.04M ﹤0.01% 2122
2022
Q4 		$816K Buy
+326,500
New +$1.05M ﹤0.01% 2656
2021
Q2 		– Sell
-162,600
Closed -$2.64M – 3600
2021
Q1 		$2.64M Buy
+162,600
New +$2.9M ﹤0.01% 2041
2020
Q4 		– Sell
-134,800
Closed -$2M – 3519
2020
Q3 		$2M Sell
134,800
-105,000
-44% -$1.64M ﹤0.01% 2136
2020
Q2 		$3.53M Sell
239,800
-812,092
-77% -$13.3M ﹤0.01% 1845
2020
Q1 		$12.3M Buy
1,051,892
+870,892
+481% +$16.4M 0.01% 1033
2019
Q4 		$4.25M Buy
+181,000
New +$4M ﹤0.01% 1956
2019
Q3 		– Sell
-97,400
Closed -$1.81M – 3538
2019
Q2 		$1.81M Buy
+97,400
New +$1.95M ﹤0.01% 2380
2018
Q4 		– Sell
-134,100
Closed -$4.24M – 3464
2018
Q3 		$4.24M Sell
134,100
-258,400
-66% -$9.62M ﹤0.01% 1910
2018
Q2 		$15.2M Buy
+392,500
New +$12.5M 0.02% 1101
2018
Q1 		– Sell
-79,800
Closed -$1.44M – 3446
2017
Q4 		$1.44M Buy
+79,800
New +$1.3M ﹤0.01% 2508
2015
Q3 		– Sell
-48,100
Closed -$1.5M – 3245
2015
Q2 		$1.5M Buy
+48,100
New +$905K ﹤0.01% 2238

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Jim Simons's HRTX Position: Q1 2026 in Review

Jim Simons reduced its Heron Therapeutics (HRTX) stake by 10% in Q1 2026, selling an estimated $229K and leaving 1,718,300 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

Jim Simons first reported a position in HRTX in Q2 2015 and has held it in 24 quarters since. The position peaked at $15.2M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Jim Simons held 1,718,300 shares of Heron Therapeutics worth $1.37M as of Q1 2026.
  • Jim Simons sold 197,600 Heron Therapeutics shares in Q1 2026, an estimated $229K.
  • Heron Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2104 holding.
  • Jim Simons first reported a position in Heron Therapeutics in Q2 2015 and has held it in 24 quarters since.
  • Jim Simons's Heron Therapeutics position peaked at $15.2M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.